Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Tucatinib is a tyrosine kinase inhibitor of HER2.”
“Based on population pharmacokinetic model estimates at steady-state, following twice daily doses of 300 mg, tucatinib was predicted to be cleared from plasma with a mean effective half- life of approximately 10.6 hours and apparent clearance of 86.11 L/h.”
“Tucatinib is metabolised primarily by CYP2C8 and to a lesser extent via CYP3A.”
Working under the parallel aged-care framework? Aged-care equivalent →